Robotic bronchoscopy in early lung cancer: a biomarker-driven platform for genomic profiling and immunotherapy-oriented decision-making.
7 affiliations
- 1Zhoukou Vocational and Technical College, Zhoukou, Henan, China.
- 2School of Pharmacy, Harbin Medical University School of Pharmacy, Harbin, China.
- 3Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 4Department of Vascular Surgery, The First Affiliated Hospital of Tsinghua University, Beijing, China.
- 5School of Medicine, Nankai University, Tianjin, China.
- 6Department of Colorectal Surgery, Tianjin Union Medical Center and the First Affiliated Hospital of Nankai University, Tianjin, China.
- 7Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Abstract
Robotic bronchoscopy is increasingly used to sample peripheral pulmonary lesions as lung cancer screening detects more small, distal, subsolid and ground-glass nodules. Most evidence has assessed the technology by diagnostic yield and safety, but these endpoints only partly capture clinical value. In early lung cancer care, the relevant question is whether bronchoscopy provides information that is sufficient for diagnosis, staging, molecular profiling and treatment-ready decision-making. This state-of-the-art review examines robotic bronchoscopy as a potential diagnosis-to-treatment platform rather than an isolated navigation device. We summarise evidence on distal airway access, procedural stability, CT-to-body divergence, tool-in-lesion confirmation, cone-beam CT, mobile cone-beam CT and radial endobronchial ultrasound. We also discuss tissue stewardship, rapid on-site evaluation, cell block preparation, next-generation sequencing, PD-L1 testing and same-session endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and, when appropriate, endoscopic ultrasound with bronchoscope-guided fine-needle aspiration (EUS-B-FNA) as determinants of molecular adequacy and clinical actionability. We propose clinically actionable yield as a pragmatic, complementary, and currently unvalidated reporting construct linking lesion access, confirmed targeting, pathological diagnosis, molecular adequacy, staging completeness, and management decisions. For prospective evaluation, Level 5 (treatment decision informed or changed) should be assessed within 30 days after the index bronchoscopic procedure or before definitive therapy, whichever occurs first. Bronchoscopic ablation is considered as a future therapeutic extension, but current evidence remains early and does not establish equivalence with surgery, stereotactic body radiotherapy or percutaneous ablation. Future studies should evaluate decision-centred and patient-centred endpoints, including molecular-testing success, repeat biopsy avoidance, time to treatment, local control, pulmonary function, quality of life and cost-effectiveness.
Related
- Biomarker-guided immunotherapy in osteosarcoma: from immune microenvironment profiling to patient stratification and combination strategies.
- Multi-omics profiling highlights RPLP0 as a potential biomarker for prognosis and response to immunotherapy in clear cell renal cell carcinoma
- Alternative to invasive bronchoscopy: validating tracheal aspirates for microbiome profiling in intensive care unit pneumonia patients
- GAN-enhanced digital twins for biomarker-guided cancer immunotherapy and adoptive cell therapy: a mini review
- Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy—A Reanalysis of OAK and POPLAR
BibTeX
@article{zhang2026robotic,
title = {{Robotic bronchoscopy in early lung cancer: a biomarker-driven platform for genomic profiling and immunotherapy-oriented decision-making.}},
author = {Dengxia Zhang and Yahui Han and Haonan Zhang and Chaoyang Yu and Shiqian Zhang and Teng Li},
journal = {Frontiers in genetics},
year = {2026},
month = oct,
doi = {10.3389/fgene.2026.1980607},
url = {https://europepmc.org/article/MED/43011611},
note = {CC BY},
}
RIS
TY - JOUR
TI - Robotic bronchoscopy in early lung cancer: a biomarker-driven platform for genomic profiling and immunotherapy-oriented decision-making.
AU - Dengxia Zhang
AU - Yahui Han
AU - Haonan Zhang
AU - Chaoyang Yu
AU - Shiqian Zhang
AU - Teng Li
PY - 2026
DA - 2026/10/27
JO - Frontiers in genetics
DO - 10.3389/fgene.2026.1980607
UR - https://europepmc.org/article/MED/43011611
AB - Robotic bronchoscopy is increasingly used to sample peripheral pulmonary lesions as lung cancer screening detects more small, distal, subsolid and ground-glass nodules. Most evidence has assessed the technology by diagnostic yield and safety, but these endpoints only partly capture clinical value. In early lung cancer care, the relevant question is whether bronchoscopy provides information that is sufficient for diagnosis, staging, molecular profiling and treatment-ready decision-making. This state-of-the-art review examines robotic bronchoscopy as a potential diagnosis-to-treatment platform rather than an isolated navigation device. We summarise evidence on distal airway access, procedural stability, CT-to-body divergence, tool-in-lesion confirmation, cone-beam CT, mobile cone-beam CT and radial endobronchial ultrasound. We also discuss tissue stewardship, rapid on-site evaluation, cell block preparation, next-generation sequencing, PD-L1 testing and same-session endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and, when appropriate, endoscopic ultrasound with bronchoscope-guided fine-needle aspiration (EUS-B-FNA) as determinants of molecular adequacy and clinical actionability. We propose clinically actionable yield as a pragmatic, complementary, and currently unvalidated reporting construct linking lesion access, confirmed targeting, pathological diagnosis, molecular adequacy, staging completeness, and management decisions. For prospective evaluation, Level 5 (treatment decision informed or changed) should be assessed within 30 days after the index bronchoscopic procedure or before definitive therapy, whichever occurs first. Bronchoscopic ablation is considered as a future therapeutic extension, but current evidence remains early and does not establish equivalence with surgery, stereotactic body radiotherapy or percutaneous ablation. Future studies should evaluate decision-centred and patient-centred endpoints, including molecular-testing success, repeat biopsy avoidance, time to treatment, local control, pulmonary function, quality of life and cost-effectiveness.
SN - 1664-8021
ER -